Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75312
UPID:
ZPR1_HUMAN
Alternative names:
Zinc finger protein 259
Alternative UPACC:
O75312; Q2TAA0
Background:
Zinc finger protein ZPR1, also known as Zinc finger protein 259, plays a pivotal role in cellular processes, including cell cycle progression, neuron differentiation, and axonal growth. It acts as a signaling molecule, facilitating the communication of proliferative growth signals and is crucial for the localization of survival motor neuron protein SMN1 in sub-nuclear bodies.
Therapeutic significance:
The protein is implicated in a rare autosomal recessive disorder characterized by growth restriction, hypoplastic kidneys, alopecia, and distinctive facies. Understanding the role of Zinc finger protein ZPR1 could open doors to potential therapeutic strategies for this condition.